177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, I0
Financial Results, Press Release
Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Announces Resignation of Board Member
Establishes an At-The-Market (ATM) Program on Nasdaq
FY 2025
Q3
Q2
Amended Annual Report
Q1
FY 2024
Notice of Late Filing for Annual Report
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload